Yupin SuputtamongkolSunanta IntaranongpaiMichael D. SmithBrian AngusWipada ChaowagulChairat PermpikulJulie A. SimpsonAmorn LeelarasameeLloyd CurtisNicholas J. WhiteMahidol UniversityNuffield Department of Clinical MedicineSappasitthiprasong HospitalBritish Bio-technology Ltd.Surin HospitalTaunton Hospital2018-09-072018-09-072000-03-01Antimicrobial Agents and Chemotherapy. Vol.44, No.3 (2000), 693-696006648042-s2.0-0033994026https://repository.li.mahidol.ac.th/handle/20.500.14594/26277Platelet-activating factor (PAF) is a potent endogenous proinflammatory mediator implicated in the pathogenesis of septic shock. A double-blind randomized placebo-controlled trial of an intravenous PAF receptor antagonist (lexipafant) was conducted with 131 adult Thai patients with suspected severe sepsis (66 of whom had positive blood cultures). Detailed serial clinical, biochemical, and cytokine measurements were performed. Lexipafant treatment was well tolerated. The 28-day mortality in the lexipafant group (61.4%) was similar to that in the placebo group (62.6%). There was also no evidence that lexipafant affected clinical or biochemical measures of disease severity or the profile of sequentially measured plasma cytokine levels. PAF may not have an important role in the pathogenesis of severe sepsis.Mahidol UniversityMedicinePharmacology, Toxicology and PharmaceuticsArticleSCOPUS10.1128/AAC.44.3.693-696.2000